Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Migraine Prevalence in Gender Identity Minorities
Headache
P14 - Poster Session 14 (11:45 AM-12:45 PM)
2-004

Despite improvements in the education of clinicians regarding LGBTQIA+ health, there are currently no large epidemiological studies available in published literature examining the prevalence of migraine in gender identity minorities, which includes people who identify as transgender, gender non-binary, genderqueer, or questioning. A recent scoping review identified only a sparse number of case reports and small cross-sectional studies regarding headache presentations in this population. Given headache disorders are the second leading cause of years lived with disability worldwide as well as the known health disparities faced by gender identity minorities, migraine is a pressing example within neurology emphasizing the need for increased research within this population to deliver evidence-based care.

This original research describes a large cross-sectional study of gender identity minorities and quantifies the prevalence of migraine across this population’s identities.

8783 subjects were identified from the electronic health record (EHR) of a multi-site academic healthcare institution based on EHR-documented gender identity, key word searches, and ICD 9 and 10 coding. A random selection of 496 subjects were reviewed in order to confirm gender identity. 328 subjects were validated and included in this study. Subjects were queried for sex assigned at birth, affirmed gender identity, age, use of gender-affirming hormones (GAH), and migraine diagnosis.

In the transwoman group (n=135), 85% were taking estrogenic GAH, and migraine prevalence was 19%. In the transman group (n=135), 84% were taking androgenic GAH, and migraine prevalence was 20%. 

The prevalence of migraine in transwomen was higher than the prevalence of cisgender men reported in previously published literature (19% versus 6%, respectively). Migraine prevalence in transmen was more similar to prior data from cisgendered women (20% versus 18%, respectively). Further research of gender identity minorities is needed to clarify the underpinnings of their experience with migraines in order to deliver quality care.
Authors/Disclosures
David Curtis Wegener, Jr., MD
PRESENTER
Dr. Wegener has nothing to disclose.
Jose R. McFaline-Figueroa, MD, PhD (Dana-Farber Cancer Institute) Dr. McFaline-Figueroa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novocure. The institution of Dr. McFaline-Figueroa has received research support from National Brain Tumor Society. The institution of Dr. McFaline-Figueroa has received research support from National Institutes of Health. The institution of Dr. McFaline-Figueroa has received research support from Robert Wood Johnson Foundation.
Robert Goldstein, MD,PhD Dr. Goldstein has nothing to disclose.